Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors That Influence Protein Binding
暂无分享,去创建一个
Nimish Patel | George L. Drusano | G. Drusano | Thomas P. Lodise | Jill M. Butterfield | Manjunath P. Pai | Thomas G. Rosano | M. Pai | N. Patel | T. Lodise | T. Rosano | J. Butterfield
[1] W. Craig,et al. Significance of serum protein and tissue binding of antimicrobial agents. , 1976, Annual review of medicine.
[2] M. Rybak,et al. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers , 1990, Antimicrobial Agents and Chemotherapy.
[3] D. Nathwani,et al. Protein binding and serum bactericidal activities of vancomycin and teicoplanin , 1995, Antimicrobial agents and chemotherapy.
[4] W. Craig. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. , 2003, Infectious disease clinics of North America.
[5] W. Craig,et al. Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .
[6] G. Rolinson,et al. Effect of protein binding on antibiotic activity in vivo. , 1983, The Journal of antimicrobial chemotherapy.
[7] D. Levine,et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[8] J. Rotschafer,et al. The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. , 1989, The Journal of burn care & rehabilitation.
[9] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.
[10] J. Leonard,et al. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease , 1996, Antimicrobial agents and chemotherapy.
[11] G. Rolinson,et al. The binding of antibiotics to serum proteins. , 1965, British journal of pharmacology and chemotherapy.
[12] W. Mcdermott,et al. The Relation of Protein Binding to the Pharmacology and Antibacterial Activity of Penicillins X, G, Dihydro F, and K. , 1947, Journal of bacteriology.
[13] M. Rybak,et al. Prediction Model to Identify Patients With Staphylococcus aureus Bacteremia at Risk for Methicillin Resistance , 2003, Infection Control & Hospital Epidemiology.
[14] George L. Drusano,et al. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.
[15] M. Rybak,et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] A. Dreisbach,et al. The effect of chronic renal failure on drug metabolism and transport , 2008, Expert opinion on drug metabolism & toxicology.
[17] J. Rotschafer,et al. Vancomycin pharmacokinetics in patients with various degrees of renal function , 1988, Antimicrobial Agents and Chemotherapy.
[18] D. Krogstad,et al. Single‐Dose Kinetics of Intravenous Vancomycin , 1980, Journal of clinical pharmacology.
[19] B. Guglielmo,et al. Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers , 1988, Antimicrobial Agents and Chemotherapy.
[20] E. Maderazo,et al. Serum protein-binding characteristics of vancomycin , 1993, Antimicrobial Agents and Chemotherapy.
[21] M. Rybak. Pharmacodynamics: relation to antimicrobial resistance. , 2006, The American journal of medicine.
[22] P. Tulkens,et al. International Journal of Antimicrobial Agents Correlation between Free and Total Vancomycin Serum Concentrations in Patients Treated for Gram-positive Infections , 2022 .
[23] Burton H. Singer,et al. Recursive partitioning in the health sciences , 1999 .
[24] G. Kaatz,et al. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin , 1991, Antimicrobial Agents and Chemotherapy.
[25] B. Ackerman,et al. Vancomycin Serum Protein Binding Determination by Ultrafiltration , 1988, Drug intelligence & clinical pharmacy.
[26] E. Lee,et al. Pharmacokinetics of Intravenous Vancomycin in Patients with End‐Stage Renal Failure , 1990, Therapeutic drug monitoring.
[27] D. Elliott,et al. Protein binding of vancomycin in a patient with immunoglobulin A myeloma , 1990, Antimicrobial Agents and Chemotherapy.
[28] Jerome J. Schentag,et al. Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections , 2004, Clinical pharmacokinetics.
[29] Jessina C. McGregor,et al. Controlling for Severity of Illness in Outcome Studies Involving Infectious Diseases: Impact of Measurement at Different Time Points , 2008, Infection Control & Hospital Epidemiology.
[30] L. Lesko,et al. Vancomycin disposition: The importance of age , 1984, Clinical pharmacology and therapeutics.
[31] L. Albrecht,et al. Vancomycin Protein Binding in Patients with Infections Caused by Staphylococcus Aureus , 1991, DICP : the annals of pharmacotherapy.
[32] H. L. Ragsdale,et al. Ultrafiltration is theoretically equivalent to equilibrium dialysis but much simpler to carry out. , 1978, Archives of biochemistry and biophysics.
[33] E. Draper,et al. APACHE II: A severity of disease classification system , 1985, Critical care medicine.